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A B S T R A C T
Myo-inositol (MI) and its isomers are used for the treatment of various neuropathological conditions.
The purpose of the present research was to study anticonvulsant properties of MI and scyllo-inositol
(SCI) on pentylenetetrazol (PTZ) induced seizures in rats. Half an hour after treatment with MI (30 mg/
kg) or SCI (5 mg/kg) seizures were induced in Wistar rats with PTZ (60 mg/kg). Control animals were
treated either by normal saline or mannitol (control polyol of the same molecular weight, 30 mg/kg),
given at the same time interval before PTZ injection, as MI/SCI groups. The anticonvulsant effects of MI/
SCI treatment were assessed by the latent period (the time from PTZ-injection to the onset of ﬁrst
seizures), and the duration and severity (score) of seizures. Themortality rate was also assessed. BothMI
and SCI treatment signiﬁcantly reduced the seizure score, seizure duration and increased the latent
period. These data suggest for strong potential of MI and SCI as the agents of antiepileptic therapy.
 2010 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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The inositols are the nine isomeric forms of cyclohexanehexol, a
group of small and chemically very stable polar molecules that
have versatile properties (reviewed in Refs. 1, 2). Myo-inositol (MI)
is the most abundant isomer and is an ubiquitous component of all
eukaryotic cells. The central nervous system (CNS) is characterized
with relatively high concentrations of MI as well as the means to
synthesize it. MI serves not only as a precursor molecule for
inositol lipid synthesis, but also as a physiologically important
osmolyte (reviewed in Ref. 2). Alteration inMI depositionmay play
role in the number of neuropathological conditions, where MI acts
either as a physiologically important osmolyte or as a precursor
molecule for phosphoinositide synthesis (reviewed in Ref. 2).
Our previous experiments have revealed that an aqueous
extract of the plant Aquilegia vulgaris (medicinal herb used in
treatment of epilepsy and insomnia) contains compounds altering
binding of ligands to the benzodiazepine and g-aminobuturic acid
(GABA) binding sites of the GABA-A receptors.3 We have identiﬁed
two constituents of this extract: (1) MI and (2) oleamide – a sleep
inducing lipid. MI inhibits 3H-muscimol binding to GABAA* Corresponding author at: Institute of Chemical Biology, Ilia State University,
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binding in vitro.3We have further shown that: (i) administration of
MI signiﬁcantly reduces the grade of PTZ or KA-induced seizures,4
and (ii) daily MI treatment prevents certain biochemical changes
triggered by KA-induced status epilepticus.5
Scyllo-inositol (SCI) is one of the inositol isomers and is present
in human brain in quantities estimated to be from 5 to 12% that of
MI.2,6 A speciﬁc epimerase in the rat and rabbit brains converts MI
to SCI.7,8 The existence of a speciﬁc enzyme for its synthesis
suggests that SCI is physiologically important. SCI inhibits
aggregation of amyloid b peptide into high molecular weight
oligomers in the brain and ameliorates several Alzheimer disease
like-phenotypes.9 In doing so SCI is more effective than epi-
inositol, whereas MI does not have any detectable effect.9
In the present study we have inquired whether or not SCI
possesses anticonvulsant properties on PTZ induced seizures. This
has not been yet reported to the best of our knowledge. The present
experimental design included MI treated group (to compare with
SCI effects), and the additional mannitol (MAN) treated control
group (sugar of the same molecular weight). Furthermore, more
detailed behavioral analysis of convulsive seizures, compared to
our initial MI study4 has been performed.
2. Methods
All animal experiments were carried out at the I. Beritashvili
Institute of Physiology and were performed in accordance withvier Ltd. All rights reserved.
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weighing 140–170 g were used throughout this study. PTZ, MAN,
MI and SCI (all from Sigma) were dissolved in normal saline before
injection.
Experiments were carried on four groups of animals. In all cases
PTZ (60 mg/kg) was administered 30 min after primary injections
of different compounds. In the ﬁrst group primary injection was
done by saline (SAL + PTZ group), in the second group by MAN
(30 mg/kg), (MAN + PTZ group), in the third group by MI (30 mg/
kg), (MI + PTZ group) and in the fourth group by SCI (5 mg/kg)
(SCI + PTZ group). All compounds were administered intraperito-
neally.
The main criterion for determination of the administered doses
of MI and SCI was that it should be in the range of 3–10% of existing
concentrations of these compounds in the rat brain.2 The used
doses more precisely were selected according to the following: (i)
in the pilot studies with 1, 2.5 and 5 mg/kg of SCI only 5 mg/kg
demonstrated a trend of anticonvulsant effect; (ii) in the pilot
studies of our previous work4 the trend of anticonvulsant activity
for MI was shown only for the dose starting from 20 mg/kg and the
dose of 30 mg/kg MI prevented biochemical changes triggered by
KA-induced SE5; (iii) the dose of MAN is equivalent to the highest
dose of inositol used in these experiments.
Each animal was placed into an individual plastic cage for
observation lasting 1 h. Mortality was estimated by the proportion
of the deathwithin 1 h and the time to onset of convulsive seizures,
duration of seizures, and the seizure severity were determined for
each animal. The convulsive seizures were scored according to a
modiﬁed Racine scoring grade from 0 to 6: 0—no motor seizures;
1—freezing, staring, mouth or facial movements; 2—head nodding
or isolated twitches, rigid posture; 3—tail extension, unilateral–
bilateral forelimb clonus; 4—rearing, in which the mice sit in an
immobile state on their rear haunches with one or both forepaws
extended; 5—clonic seizures, loss of posture, jumping and
forepaws extended; 6—tonic seizures with hindlimb extension[see
10,11]. Each animal was assigned the score of the most severe
seizure observed.
Each group consisted of 10 animals. In each replication of the
experiment all four groups were tested. There were ﬁve replica-
tions of the experiment. Thus, in total 200 animals were used in
this study. The calculation of the number of experimental animals
and the sample size was based on the data obtained from our
previous study.4
2.1. Statistical analysis
The effect of tested compounds on the seizure grade was
evaluated by Kruskal–Wallis test. Planned comparisonsweremade
by Mann–Whitney test.
The mortality rate, latent period, and duration and severity of
seizures were analyzed by one-way analysis of variances (one-way
ANOVA). The data fromanimalswhich did not develop PTZ induced
SE were excluded from the analysis of latent period. Planned
comparisons between groups were made using t-tests. All
statistical tests were two-tailed.
3. Results
3.1. PTZ induced seizure scores
The effect of experimental factor on the seizure score was
statistically signiﬁcant (H = 13.23, DF = 3, P = 0.0043). MI and SCI
signiﬁcantly reduced the seizure score compared to saline control
(MI + PTZ vs SAL + PTZ, W = 2939.5, P = 0.0043; SCI + PTZ vs
SAL + PTZ, W = 2935.0, P = 0.0048). Both isomers of inositol also
signiﬁcantly decreased the severity of seizures as compared toMAN + PTZ group (MI + PTZ vs MAN + PTZ, W = 2503.5, P = 0.046;
SCI + PTZ vs MAN + PTZ, W = 2540.0, P = 0.023) (see Fig. 1A).
3.2. Latent period
The latency of seizure onset signiﬁcantly changed under
experimental conditions (see Table 1). MI treatment signiﬁcantly
delayed the onset of seizures compared to SAL + PTZ group
(t = 2.26, P = 0.027) and MAN + PTZ group (t = 3.45, P = 0.001).
The latent period was increased in SCI + PTZ group as compared to
MAN + PTZ group (t = 2.03, P = 0.045). No other differences were
statistically signiﬁcant (see also Fig. 1B).
3.3. Seizure duration
This behavioral parameter is also signiﬁcantly affected by
experimental group (see Table 1). MI pretreatment signiﬁcantly
decreased seizure duration as compared to SAL + PTZ and
MAN + PTZ groups (t = 2.48, P = 0.015 and t = 1.99, P = 0.049,
respectively, Fig. 1C). SCI also signiﬁcantly decreased the duration
of seizures as compared to SAL + PTZ group (t = 2.00, P = 0.048). The
difference between the MAN + PTZ and SCI + PTZ groups is not
signiﬁcant (P = 0.774). Other differences between the groups also
have not been statistically signiﬁcant.
3.4. Mortality rate
No signiﬁcant differences have been observed between the
groups for mortality rate by ANOVA analysis (see Table 1).
4. Discussion
The present study provides for the ﬁrst time evidence of
anticonvulsant action of SCI and expands our knowledge on
anticonvulsant properties of MI. Both inositols signiﬁcantly
decrease the PTZ induced seizure scores, delay the latent period
for the onset of seizures, and decrease the seizure duration.
According to our pilot studies no anticonvulsive features are
displayed byMI in the concentration range 5–15 mg/kg. Thus SCI is
more effective at lower concentrations. Despite a six times higher
concentration of MI compared to SCI in the present experiments,
no signiﬁcant differences were observed between MI + PTZ and
SCI + PTZ groups. Inositol stereoisomers have different distribution
of hydroxyl groups across the surfaces of the sugar ring and these
differences could account for different effective concentrations of
MI and SCI on PTZ induced seizures.
The effects of MI and SCI in our experiments are speciﬁc to MI
and SCI as inositols. No statistically signiﬁcant differences were
found between two sham groups: saline and MAN (a polyol with a
similar molecular weight to those of MI and SCI), and both groups
were signiﬁcantly different from the MI and SCI groups with
respect to nearly all of the studied parameters.
The mechanism of anticonvulsant effects of inositols is not
entirely clear. However, it has been widely recognized that
depletion of levels of inositols has proconvulsant effect. Thus,
proconvulsant effect of lithium has been attributed to its ability to
block the action of inositol monophosphatase (IMPase).12 Well-
known psychotrophic action of lithium in mania could be
attributed to its block of IMPase, with concomitant decrease of
free inositol (inositol depletion hypothesis[see 12]). Previous
studies suggest that proconvulsant effects of lithium can be
reversed by MI.13–15 In all of these studies 10 mg of MI was
administered intraventricularly (i.c.v.) or by peripheral adminis-
tration of the corresponding dose (10 g/kg). According to these
studies, to build the same levels of MI in human as in the rat, and
achieve therapeutic effect, intake of 100 g inositol would be
[()TD$FIG]
Fig. 1. Effects of MI and SCI on the seizures induced by pentylentetrazol (PTZ). (A) Seizure score was measured for each animal and was assigned the score of the most severe
seizure observed. Seizure scores are presented as mean  SEM. All data between the groups were compared with the Mann–Whitney test. (B) The latency to the ﬁrst observable
seizure activity wasmeasured for each animal and averaged in each treatment group. Data are provided as mean  SEM. All data between the groups are compared by two-tailed t-
test. (C) The duration of observable seizure activity wasmeasured for each animal andmean values  SEM are provided for each group. Groups were compared using a two-tailed t-
test.
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used for the treatment of depression in humans by orally given
inositol16 or 300 times higher than the doses used in our present
and previous studies in rats.4,5 These high doses of MI exceed the
therapeutically safe concentrations and can be toxic.15 All this
questions the expediency of high doses MI treatment for possible
therapeutic use in humans.
However, the potential of SCI as a potential antiepileptic agent
remains to be uncovered. According to a single report on
antiepileptic features of SCI, high doses of SCI (10 mg) were
administered i.c.v. and no anticonvulsant activity was observed in
lithium–pilocarpine model of seizures.17 The discrepancy between
above-mentioned study and our own may be due to different
models of epilepsy, doses or routes of administration of SCI.Table 1
Summary of one-way ANOVA results. F, variance ratio from one-way ANOVA; P,
probability.
Latency to seizures F3,177 4.71
P 0.003
Seizure duration F3,196 2.86
P 0.038
Mortality rate F3,19 0.78
P 0.520What could be the mechanisms of MI and SCI action under our
experimental conditions? We have previously shown that MI in
vitro changes the binding of 3H muscimol and 3H MK-801 to rat
brain membranes3 and therefore modulation of GABA-A and
NMDA receptors could be involved in anticonvulsant features of
MI. During intense neuronal excitation massive inﬂux of Na+, Ca2+
and Cl takes place, which leads to inward ﬂow of water and
cellular swelling.18,19 Under such conditions various enzymes
cannot function normally.20 In compensation for this disturbed
condition, neuronal and other cells accumulate high concentra-
tions of small organic osmolytes, including MI, which do not
perturb the functioning of the enzymes[21, 22, reviewed in 23].
This mechanism as well could be one of the factors in the
anticonvulsant effects of MI. Some data, obtained from the
experiments on pilocarpine–lithium models of seizures, also
indicate that mechanism other than phosphoinositide depletion
contributed to the MI response.15 No data are available at present
about the mechanism of action of SCI.
In conclusion our present results indicate that MI and SCI in the
range of physiological concentrations possess anticonvulsant
properties on PTZ induced convulsions. Our previous data
indicated anti-epiloptegenic and neuroprotective features of
MI.5,24 Based on existing and present data we propose that, in
M. Nozadze et al. / Seizure 20 (2011) 173–176176addition to other functions, MI and SCI are endogenous antic-
onvulsants and that their actions should be explored in a broader
range of epilepsy models.
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